Form 4 Filing for Gary J. Nabel - Candel Therapeutics, Inc.

This filing details a Form 4 submission by Gary J. Nabel, a director at Candel Therapeutics, Inc. (CADL). On June 23, 2026, Mr. Nabel was granted a stock option to acquire 32,000 shares of the company's Common Stock at an exercise price of $9.08 per share. This option is subject to time-based vesting, with full exercisability contingent upon the earlier of June 23, 2027, or the next Annual Meeting of Stockholders. However, vesting will cease if Mr. Nabel resigns from the Board of Directors, unless the Board determines otherwise. The option has an expiration date of June 23, 2036. Following this transaction, Mr. Nabel holds 32,000 shares under this option agreement.